Clin2
NCT07341737Possibly a fitRecruiting

SL-28 for advanced solid tumors that haven’t responded to treatment

Head & Neck CancerPancreas CarcinomaPancreas Cancer, MetastaticLung AdenocarcinomaLung Cancer (NSCLC)Lung Cancer (Non-Small Cell)Esophageal CancerStomach (Gastric) Cancer

Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.

This trial tests a new drug, SL-28, for people with advanced solid tumors that haven’t responded to or cannot be treated with standard therapies. It aims to find a safe dose and see if the drug can help shrink or slow the growth of your cancer.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
60 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be 18 or older and have an advanced solid tumor that cannot be removed by surgery.
  • Standard treatments (like chemo, immunotherapy, or targeted therapy) should have stopped working, caused bad side effects, or you have chosen not to take them.
  • You need to be in fairly good physical shape (able to take care of yourself and do light activities).
  • Your kidneys, liver, and blood counts must be working well enough in the last blood tests.
  • You should not have serious heart disease, uncontrolled infections, or other major health conditions that would make the trial unsafe.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07650357Not yet recruiting· Phase 1
CLSP 5282 for Advanced Solid Tumors With KRas G12V Mutation

This early-stage trial tests a new immunotherapy called CLSP 5282 designed for patients with advanced solid cancers that have a specific genetic change (KRas G12V mutation) and a matching immune marker (HLA-A*03:01). The treatment aims to help your immune system recognize and attack cancer cells.

Durham, North Carolina
NCT07358884Not yet recruiting· Phase 1
Testing QLS5316 for advanced solid tumors

This study tests a new experimental drug called QLS5316 for people with advanced solid tumors that have not responded to standard treatments. The drug works like a 'smart bomb'—it seeks out and delivers medicine directly to cancer cells.

NCT06771219Recruiting· Phase 1
Testing SLV-154 for advanced cancers

This trial tests a new drug called SLV-154 for people whose advanced cancer has not responded to standard treatments. The goal is to see if SLV-154 can shrink tumors or slow cancer growth.

Newport Beach, California
NCT07108114Recruiting· Phase 1
SLV-324 for advanced solid tumors that have spread

This phase 1 trial tests a new drug called SLV-324 for people with solid tumors that have spread and are no longer responding to standard treatments. The goal is to see if the drug is safe and works against the cancer.

Newport Beach, California
NCT05902988Recruiting· Phase 1/Phase 2
Study of VLS-1488 for advanced cancers

This early-phase study tests VLS-1488, a new cancer medicine, in people with advanced cancers that have limited treatment options. It may help by finding a safe dose and whether it can shrink or control tumors.

Los Angeles, California
NCT06223256Recruiting· Phase 1
NBL-028 for advanced solid tumors with CLDN6

This trial tests a new drug called NBL-028 in people with advanced solid tumors that have a specific protein (CLDN6). It is for those who have already tried standard treatments. The goal is to see how safe and effective the drug is.

Shijiazhuang, Hebei

Hear when a new Pancreas Cancer, Metastatic trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.